PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2013 | 8 | 6 | 822-829
Tytuł artykułu

Predictors of treatment response in patients with hepatitis C 1b genotype

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Wydawca

Czasopismo
Rocznik
Tom
8
Numer
6
Strony
822-829
Opis fizyczny
Daty
wydano
2013-12-01
online
2013-12-06
Twórcy
  • Department of Internal Medicine, University of Tartu, L. Puusepa 6, 51014, Tartu, Estonia
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
Bibliografia
  • [1] World Health Organization Viral Cancers: Hepatitis C virus. Accessed 2010 May 28. Available from: URL: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html#disease%20burden
  • [2] Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, 2005, 42(4), 962–973 http://dx.doi.org/10.1002/hep.20819[Crossref]
  • [3] Lavanchy D., Evolving epidemiology of hepatitis C virus, Clin. Microbiol. Infect., 2011, 17(2), 107–115 http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x[Crossref][WoS]
  • [4] Esteban J.I., Sauleda S., Quer J., The changing epidemiology of hepatitis C virus infection in Europe, J. Hepatol., 2008, 48, 148–162 http://dx.doi.org/10.1016/j.jhep.2007.07.033[Crossref]
  • [5] Tallo T., Norder H., Tefanova V., Krispin T., Schmidt J., Ilmoja M., et al., Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominanting subtype with time, J. Med. Virol., 2007, 79(4), 374–382 http://dx.doi.org/10.1002/jmv.20828[WoS][Crossref]
  • [6] Zusinaite E., Krispin T., Raukas E., Kiiver K., Salupere R., Ott K., et al., Hepatitis C virus genotypes in Estonia, APMIS, 2000, 108(11), 739–746 http://dx.doi.org/10.1034/j.1600-0463.2000.d01-23.x[Crossref]
  • [7] Tefanova V., Tallo T., Kutsar K., Priimgi L., Urgent action needed to stop spread of hepatitis B and C in Estonian drug users, Euro Surveill., 2006, 11, E060126.3
  • [8] Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B., Diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 2009, 49, 1335–1374 http://dx.doi.org/10.1002/hep.22759[Crossref]
  • [9] EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J. Hepatol., 2011, 55, 245–264
  • [10] Shiffman M.L., Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders, Curr. Gastroenterol. Rep., 2006, 8(1), 46–52 http://dx.doi.org/10.1007/s11894-006-0063-z[Crossref]
  • [11] Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 2001, 358, 958–965 http://dx.doi.org/10.1016/S0140-6736(01)06102-5[Crossref]
  • [12] Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L. Jr, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med., 2002, 347, 975–982 http://dx.doi.org/10.1056/NEJMoa020047
  • [13] Hadziyannis S.J., Sette H.Jr., Morgan T.R., Balan V., Diago M., Marcellin P., et al., Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann. Intern. Med., 2004, 140(5), 346–355 http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010
  • [14] McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N. Engl. J. Med., 2009, 361(6), 580–593 http://dx.doi.org/10.1056/NEJMoa0808010[WoS]
  • [15] Ferenci P., Optimal treatment duration for patients with HCV genotype 1 infection, J. Viral. Hepat., 2012, 19(Suppl 1), 7–13 http://dx.doi.org/10.1111/j.1365-2893.2011.01522.x[Crossref]
  • [16] Yu J.W., Sun L.J., Zhao Y.H., Kang P., Yan B.Z., Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment, Int. J. Infect. Dis., 2011, 15(11), 740–746 http://dx.doi.org/10.1016/j.ijid.2011.05.018[Crossref]
  • [17] Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al., Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy, Hepatology, 2003, 37(3), 600–609 http://dx.doi.org/10.1053/jhep.2003.50106[Crossref]
  • [18] Zeuzem S., Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann. Intern. Med., 2004, 140(5), 370–381
  • [19] Foster G.R., Fried M.W., Hadziyannis S.J., Messinger D., Freivogel K., Weiland O., Predicting of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin, Scand. J. Gastroenterol., 2007, 42(2), 247–255 http://dx.doi.org/10.1080/00365520600955526[WoS][Crossref]
  • [20] Hoofnagle J.H., Wahed A.S., Brown R.S.Jr., Howell C.D., Belle S.H., Virahep-C Study Group, Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection, J. Infect. Dis., 2009, 199(8), 1112–1120 http://dx.doi.org/10.1086/597384[Crossref]
  • [21] Saludes V., Bracho M.A., Valero O., Ardevol M., Planas R., Gonzalez-Candelas F., et al., Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors, PloS One, 2010, 5(11), e14132 http://dx.doi.org/10.1371/journal.pone.0014132[Crossref]
  • [22] Puig-Basagoiti F., Forns X., Furcić I., Ampurdanés S., Giménez-Barcons M., Franco S., et al., Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C, J. Gen. Virol., 2005, 86(Pt 4), 1067–1075 http://dx.doi.org/10.1099/vir.0.80526-0[Crossref]
  • [23] Villela-Nogueira C.A., Perez R.M., de Segadas Soares J.A., Coelho H.S., Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin, J. Clin. Gastroenterol., 2005, 39(8), 728–730 http://dx.doi.org/10.1097/01.mcg.0000174025.19214.32[Crossref]
  • [24] Jacobson I.M., Brown R.S. Jr., Freilich B., Afdhal N., Kwo P.Y., Santoro J., et al., Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial, Hepatology, 2007, 46(4), 971–981 http://dx.doi.org/10.1002/hep.21932[Crossref]
  • [25] Poordad F., Reddy K.R., Martin P., Rapid virologic response: a new milestone in the management of chronic hepatitis C, Clin. Infect. Dis., 2008, 46(1), 78–84 http://dx.doi.org/10.1086/523585[WoS][Crossref]
  • [26] Fried M.W., Hadziyannis S.J., Shiffman M.L., Messinger D., Zeuzem S., Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection, J. Hepatol., 2011, 55(1), 69–75 http://dx.doi.org/10.1016/j.jhep.2010.10.032[Crossref][WoS]
  • [27] Clark P.J., Thompson A.J., McHutchison J.G., IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies, Am. J. Gastroenterol., 2011, 106(1), 38–45 http://dx.doi.org/10.1038/ajg.2010.370[WoS][Crossref]
  • [28] Bedossa P., Poynard T., An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology, 1996, 24(2), 289–293 http://dx.doi.org/10.1002/hep.510240201[Crossref]
  • [29] Backus L.I., Boothroyd D.B., Phillips B.R., Belperio P., Halloran J., Mole L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C, Clin. Gastroenterol. Hepatol., 2011, 9, 509–516 http://dx.doi.org/10.1016/j.cgh.2011.03.004[Crossref]
  • [30] Brjalin V., Salupere R., Tallo T., Kuznetsova T., Priimägi L., Tefanova V., Efficacy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naïve Estonian patients with chronic hepatitis C, Cent. Eur. J. Public Health, 2012, 20(2), 150–155
  • [31] Lee S.S., Bain V.G., Peltekian K., Krajeden M., Yoshida E.M., Deschenes M., et al., Treating chronic hepatitis C with pegylated interferon alfa- 2a (40 KD) and ribavirin in clinical practice, Aliment. Pharmacol. Ther., 2006, 23, 397–408 http://dx.doi.org/10.1111/j.1365-2036.2006.02748.x[Crossref]
  • [32] Mauss S., Hueppe D., John C., Goelz J., Heyne R., Moeller B., et al., Estimating the likelihood of sustained virological response in chronic hepatitis C therapy, J. Viral. Hepat., 2011, 18, 81–90 http://dx.doi.org/10.1111/j.1365-2893.2010.01372.x[Crossref]
  • [33] Weich V., Herrmann E., Chung T.L., Sarrazin C., Hinrichsen H., Buggisch P., et al., The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection, J. Gastroenterol., 2011, 46(12), 1427–1436 http://dx.doi.org/10.1007/s00535-011-0458-y[WoS][Crossref]
  • [34] Marcellin P., Cheinquer H., Curescu M., Dusheiko G.M., Ferenci P., Horban A., et al., High sustained virologic response rates in rapid virologic response patients in the large realworld PROPHESYS cohort confirm results from randomized clinical trials, Hepatology, 2012, 56(6), 2039–2050 http://dx.doi.org/10.1002/hep.25892[Crossref]
  • [35] Navaneethan U., Kemmer N., Neff G.W., Predicting the probable outcome of treatment in HCV patients, Therap. Adv. Gastroenterol., 2009, 2(5), 287–302 http://dx.doi.org/10.1177/1756283X09339079[Crossref]
  • [36] Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al., Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa- 2a plus ribavirin, Gastroenteroly, 2006, 130, 1086–1097 http://dx.doi.org/10.1053/j.gastro.2006.02.015
  • [37] Lindsay K.L., Morishima C., Wright E.C., Dienstag J.L., Shiffman M.L., Everson G.T., et al., Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C, Clin. Gastroenterol. Hepatol., 2008, 6(2), 234–241 http://dx.doi.org/10.1016/j.cgh.2007.11.020[Crossref][WoS]
  • [38] Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al., Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection, N. Engl. J. Med., 1996, 334(2), 77–81 http://dx.doi.org/10.1056/NEJM199601113340203[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0221-2
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.